Spain's Faes aims for Asian drug launch, OTC selloff; Jury adds $90M punitive award to Teva, Baxter tab;

@FiercePharma: Weak cancer meds, Tamiflu take bite out of Roche sales. Story | Follow @FiercePharma

> Spain's Faes Farma plans to launch its bilastine allergy drug in Asia and sell off OTC drugs to offset the sales hit from government cost-cutting. News

> A jury levied $90 million in punitive damages against Teva Pharmaceutical Industries ($TEVA) and Baxter International ($BAX) in the third trial over a hepatitis C outbreak linked to the anesthetic propofol. Story

> Onyx Pharmaceuticals shares climbed for the second day in a row after a legal settlement with Bayer prompted BMO Capital Markets to upgrade the stock to "outperform." Item

> Russia expanded its essential drugs list with a number of branded cancer drugs, including Novartis' ($NVS) Afinitor, Eli Lilly's ($LLY) Alimta, Bayer's Nexavar and AstraZeneca's ($AZN) Iressa. Article

> Belgian distributor Omega Pharma tossed its full-year forecast after turning in weak third-quarter sales. Report

> Standard & Poor's rated Mylan's ($MYL) proposed $2.25 billion senior credit facility at BBB. Story

> AstraZeneca said it bought back 500,256 shares at a price of 2979 pence per share, as part of its ongoing stock repurchase program. Report

Biotech News 

@FierceBiotech: Medivation chief amps up rhetoric on Ph3 prostate cancer drug. Story | Follow @FierceBiotech

@RyanMFierce: Bi-specific antibody upstart Oncobiologics charts expansion in new NJ labs. Report | Follow @RyanMFierce

@MaureenFierce: Option-based deals: How biotechs and big pharmas share R&D risks. Article  | Follow @MaureenFierce

> Medivation chief amps up rhetoric on Ph3 prostate cancer drug. Item

> Depomed shares crater on another Phase III miss for hot-flash drug. Story

And Finally... Pfizer has teamed up with Humana to track care and costs for elderly patients with chronic pain, cardiovascular problems and Alzheimer's disease. Report